How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Draft guidance consultation

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about donanemab

Marketing authorisation indication

2.1

Donanemab (Kisunla, Eli Lilly and Company) is indicated 'for the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease in adult patients that are apolipoprotein E ε4 (APOE ε4) heterozygotes or non-carriers'.

Dosage in the marketing authorisation

2.2

The dosage schedule will be available in the summary of product characteristics for donanemab.

Price

2.3

The list price of donanemab concentrate for solution for infusion is confidential until published by the Department for Health and Social Care.

2.4

The company has a commercial arrangement, which would have applied if the technology had been recommended.